Despite Biocon's assurances that the findings would not impact its business, investor sentiment appeared cautious.

The inspection, which took place between September 23 and September 27, 2024, concluded with 4 observations from the ...

Biocon shares fell 2% to Rs 361.5 after the USFDA issued four observations following an inspection of its Bengaluru API facility. The company will address these within the stipulated time and does not ...

Biocon has entered a partnership with Tabuk for the commercialisation of glucagon-like peptide-1 (GLP-1) products in the ...

Biocon's Bengaluru-based API facility received four observations from the USFDA following an inspection. The company plans to ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, fund raising and ...

Under the terms of this agreement, Biocon will develop and manufacture the products, and Tabuk Pharmaceuticals will hold the ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data ...

Under this agreement, Tabuk Pharmaceuticals will market Biocon's GLP-1 products across Saudi Arabia and other countries in ...

Biocon Ltd has entered a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to market GLP-1 ...

Pharma company Biocon is set to announce its financial results for the quarter ended September 30, 2024, tomorrow, October 1 ...

This partnership aligns with both companies' strategies to address the growing demand for effective diabetes treatments in ...